Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annals of Oncology

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdv071PMID 25722380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial.

  2014cited by this paper
• Patient-derived breast tumor xenografts facilitating personalized cancer therapy

  2013cited by this paper
• Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.

  2013cited by this paper
• Role of macrophage targeting in the antitumor activity of trabectedin.

  2013cited by this paper
• BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

  2013cited by this paper
• Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

  2012cited by this paper
• Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

  2010cited by this paper
• "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

  2008cited by this paper
• Improved survival in BRCA2 carriers with ovarian cancer

  2006cited by this paper
• DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743).

  2006cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.

  2005cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.

  1999cited by this paper

• Liposome-engineered therapeutics: A promising frontier in ovarian cancer treatment.

  2025cites this paper
• Synergetic approaches of fucoidan and trabectedin complex coated PLGA nanoparticles effectively suppresses proliferation and induce apoptosis for the treatment on non-small cell lung cancer

  2024cites this paper
• Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?

  2024cites this paper
• Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

  2024cites this paper
• The impact of PARP inhibitors in the whole scenario of Ovarian Cancer management: a Systematic Review and Network Meta-Analysis.

  2023cites this paper
• INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

  2023cites this paper
• A systematic review of emerging technologies to enhance the treatment of ovarian cancer

  2023cites this paper
• Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

  2023cites this paper
• Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials.

  2023cites this paper
• Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs

  2023cites this paper
• Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers

  2022cites this paper
• DNA repair and damage pathways in mesothelioma development and therapy

  2022cites this paper
• Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine

  2022cites this paper
• Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma

  2022cites this paper
• Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.

  2021cites this paper
• Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes

  2021cites this paper
• Real-world experience with trabectedin for the treatment of recurrent ovarian cancer

  2021cites this paper
• A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

  2021cites this paper
• Ovarian Cancer: Primary Advanced and Recurrent Disease

  2021cites this paper
• A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum‐Sensitive Ovarian Cancer

  2020cites this paper
• A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.

  2020cites this paper
• Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.

  2020cites this paper
• The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective.

  2019cites this paper
• Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

  2019cites this paper
• Ovarian Cancer Genetics and Implications for Imaging and Therapy.

  2019cites this paper
• Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening

  2019cites this paper
• УДК 618.11-006.6 МОЛЕКУЛЯРНАЯ ХАРАКТЕРИСТИКА СЕРОЗНОЙ АДЕНОКАРЦИНОМЫ ЯИЧНИКА: ЗНАЧЕНИЕ ДЛЯ ДИАГНОСТИКИ И ЛЕЧЕНИЯ

  2019cites this paper
• Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.

  2019cites this paper
• The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery.

  2019cites this paper
• Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

  2019cites this paper
• Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

  2019cites this paper
• Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

  2019cites this paper
• Trabectedin in Ovarian Cancer: is it now a Standard of Care?

  2018cites this paper
• Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application

  2018cites this paper
• Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcription

  2017cites this paper
• Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.

  2017cites this paper
• Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience

  2017cites this paper
• PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.

  2017cites this paper
• Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

  2017cites this paper
• BRCA mutations in the manifestation and treatment of ovarian cancer.

  2017cites this paper
• When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.

  2017cites this paper
• Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.

  2017cites this paper
• The efficacy of trabectedin in treating ovarian cancer

  2017cites this paper
• BRCA mutations in the manifestation and treatment of ovarian cancer

  2017cites this paper
• 1. Targeting Enzymatic Pathways with Marine-Derived Clinical Agents

  2017cites this paper
• Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

  2017cites this paper
• The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer

  2017cites this paper
• Trabectedin mechanism of action and platinum resistance: molecular rationale.

  2017cites this paper
• Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma

  2016cites this paper
• Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition

  2016cites this paper
• Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment

  2016cites this paper
• Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin

  2016cites this paper
• Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.

  2016cites this paper
• Trabectedin as a chemotherapy option for patients with BRCA deficiency.

  2016cites this paper
• Unique features of trabectedin mechanism of action

  2016cites this paper
• Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair

  2016cites this paper
• Advanced ovarian cancer: 20 years of ovarian cancer treatment.

  2016cites this paper
• Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge

  2016cites this paper
• Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation

  2016cites this paper
• Trabectedin for the treatment of breast cancer

  2016cites this paper
• Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products

  2015cites this paper
• Трабектедин - лиганд узкой бороздки ДНК

  2015cites this paper
• Protein Recognition in Drug-Induced DNA Alkylation: When the Moonlight Protein GAPDH Meets S23906-1/DNA Minor Groove Adducts

  2015cites this paper
• Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin

  2015cites this paper